1. Antiarrhythmic Drugs in AF

2. Introduction

3. Clinical Status and Concurrent Conditions Influence Selection of Class IA AADs

4. Selection According to Patient-Specific Considerations and AAD Safety Profile

5. Real-World Data From Germany 62 Cardiology Practices: 2010 to 2017

6. Interpreting Observational Study Data

7. Analysis of Concurrent Medications With NOAC for Nonvalvular AF: Major Bleeding Risk

8. Analysis of Patients With AF in Sweden Risk of Major Bleeding

9. Analysis of Patients With AF in Sweden Primary Endpoint

10. Analysis of >44,000 Patients With AF in Sweden Composite Endpoint

11. AADs for Maintaining Sinus Rhythm After Cardioversion of AF: Cochrane Analysis

12. Network Meta-Analysis Data From 40 Randomized Controlled Trials

13. Summary

14. Abbreviations